The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
Authors
Hruschka, Natascha
Subijana, Maria
Graña-Castro, Osvaldo
Brunet, Laia Paré
Chernukhin, Igor
Sagrera, Ana
De Reynies, Aurelien
Kloesch, Bernhard
Chin, Suet-Feung
Burgués, Octavio
Bermejo, Begoña
Cejalvo, Juan Miguel
Sutton, Joe
Publication Date
2020-06-25Journal Title
Oncogene
ISSN
0950-9232
Publisher
Nature Publishing Group UK
Volume
39
Issue
32
Pages
5455-5467
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Hruschka, N., Kalisz, M., Subijana, M., Graña-Castro, O., Del Cano-Ochoa, F., Brunet, L. P., Chernukhin, I., et al. (2020). The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene, 39 (32), 5455-5467. https://doi.org/10.1038/s41388-020-1376-3
Description
Funder: Spanish Ministry of Science, Innovation, and University. BFU2016-80570-R
Funder: Cancer Research UK (CRUK); doi: https://doi.org/10.13039/501100000289
Funder: Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer); doi: https://doi.org/10.13039/501100002704
Abstract
Abstract: As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factor GATA3 is a paradigm of this. We investigated the functions of the most common GATA3 mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called “neoGATA3,” associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application.
Keywords
Article, /631/67/1347, /631/67/68, /13/1, /13/51, /38/39, /82/80, /96/106, /45/22, /45/90, article
Sponsorship
Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) (P27361-B23, P27361-B23, P27361-B23)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) (SAF2011-29530, SAF2011-29530, SAF2015-70553-R)
Identifiers
s41388-020-1376-3, 1376
External DOI: https://doi.org/10.1038/s41388-020-1376-3
This record's URL: https://www.repository.cam.ac.uk/handle/1810/310059
Rights
Licence:
https://creativecommons.org/licenses/by/4.0/